We investigated the haemodynamic effects and the efficacy of a continuous infusion of dexmedetomidine without a loading dose in 50 patients having had cardiac surgery (n=33), complex major surgery (n=9) and multiple trauma (n=8). The mean age was 60 (±16) years, and the mean APACHE II score was 13 (±5). Dexmedetomidine was commenced at an initial rate of 0.2 to 0.4 µg/kg/h (depending on whether anaesthetic or sedative agents had already been used) and rescue analgesia and sedation was administered with morphine and midazolam respectively. Propofol was used if additional sedation was needed. Sedation was targeted to a modified Motor Activity Assessment Score. Eighty percent of patients required no or "minimal" rescue therapy (<10 mg midazolam /day and/or <10 mg morphine/day and/or <100 mg propofol/day). The cardiac surgery group needed the least rescue therapy. A statistically significant but clinically unimportant reduction in mean heart rate and mean systolic blood pressure was observed over the first six hours (P<0.0001, and P=0.009 respectively) . The baseline heart rate of 85 (±17) beats per minute (bpm), fell to a low of 78 (±13) bpm at four hours and then remained stable throughout the infusion period. The systolic blood pressure fell from 125 (±22) mmHg to a low of 112 (±20) mmHg at 1.5 hours with minimal change afterwards.
Dexmedetomidine is a highly selective alpha 2 adrenoreceptor agonist licensed for sedation of intubated post-surgical patients for up to 24 hours. In addition, it has anxiolytic, sympatholytic and analgesic effects without significant respiratory depression so that it may continue to be used after tracheal extubation 1, 2 . It has a relatively high ratio of alpha 2 : alpha 1 activity (8 times that of clonidine) so that it has more potent sedative effects than cardiovascular effects. When used for up to 24 hours in post surgical patients it has been shown to be efficacious and to not adversely affect cardiovascular status or adrenal response to synthetic adrenocorticotrophic hormone 3, 4 .
The manufacturer's (Abbott Australasia Pty Ltd) recommended practice is to give a loading dose of 1 µg/kg over 10 to 20 minutes. In a study of 66 postsurgery patients receiving this loading dose, 11 out of 18 unwanted haemodynamic effects (mean arterial pressure less than 60 mmHg or heart rate less than 50 beat/min) occurred during loading 5 . A reduction in loading dose was suggested following a study in medical patients, especially if other sedative agents had been used prior to starting dexmedetomidine 6 . A recent study using a loading dose commenced at sternal closure following coronary artery bypass surgery demonstrated a transient increase in mean systolic blood pressure (SBP) during the first 20 minutes followed by a trough value after a further 10 minutes 7 .
The aim of this study was to investigate the benefits of dexmedetomidine in a group of complex postoperative and trauma patients with co-morbidities and also to establish whether omission of the loading dose would reduce haemodynamic adverse effects without reducing efficacy.
MATERIALS AND METHODS
Patients aged 18 years or over and expected to require sedation and/or analgesia for up to 24 hours were included. Informed consent was obtained for all patients who had dexmedetomidine for greater than 24 hours, as directed by the South Eastern Sydney Area Health Service Research Ethics Committee. Exclusion criteria were: continued use of neuromuscular blocking agents in the Intensive Care Unit other than for endotracheal intubation; known or suspected allergy to dexmedetomidine or other study drug; current treatment with an alpha 2 agonist or antagonist; participation in a trial with any other experimental drug within 30 days prior to ICU admission; pregnancy or lactation; and subarachnoid or epidural drug administration.
Dexmedetomidine HCl (Abbott Australasia Pty Ltd, Kurnell, N.S.W.) was supplied in 2 ml ampoules at a concentration of 100 µg/ml. The drug was diluted with normal saline to a body-mass-corrected concentration, whereby 1 ml/h of infusion was equal to 0.1 µg/kg/h, administered through a syringe pump via a central venous line.
After arrival to intensive care, dexmedetomidine was infused without a loading dose, at a rate of 0.2 to 0.4 µg/kg/h. The lower starting infusion rate was used in postoperative patients who were experiencing the residual effect of a general anaesthetic. As the pharmacokinetic profile of dexmedetomidine had been described only in normothermic patients, postcardiac surgery patients were only commenced on dexmedetomidine once normothermic. If other sedative or analgesic agents were being used, these were weaned as tolerated after the first hour. The infusion rate could be increased up to 0.7 µg/kg/h or decreased to 0.2 µg/kg/h via a nurse-driven protocol targeted to a modified Motor Activity Assessment Scale (mMAAS) of zero or 1 ( Table 1) 8 . Dexmedetomidine was continued until sedation was no longer needed, or the patient required a continuous infusion of therapeutic rescue sedation and/or analgesia. Dexmedetomidine boluses were disallowed for rescue effect. This was achieved with midazolam 1.0 to 2.5 mg boluses and/or morphine 2.5 mg boluses which could be administered when the maximum infusion rate had been reached or otherwise if deemed clinically indicated. For refractory cases, propofol and analgesic infusions were used as clinically indicated.
Heart rate and invasive blood pressure were monitored continuously and recorded every fifteen minutes for the first two hours, then every hour until discharge from ICU. In patients where a pulmonary artery catheter was in place, pulmonary artery pressures were recorded hourly until removal. Thermodilution cardiac output measurements were performed when clinically indicated. All patients were managed with routine care, which included daily examination, ECG, and blood biochemistry and haematology laboratory tests.
Statistics
Results are expressed as mean (±SD) or median (range) unless otherwise stated. Statistical analysis was performed using Chi square test and ANOVA to compare characteristics, repeated measures ANOVA to assess changes in heart rate and blood pressure over time, and Mann Whitney U test and Kruskal-Wallis test to compare dosage between patients. StatView for Windows (Version 5.0.1 SAS Institute Inc, Cary, NC, U.S.A.) software was used in all calculations. A P<0.05 was considered to be statistically significant.
RESULTS

Patient Groups
Fifty patients were included and divided into three groups; cardiac surgery (n=33), complex surgical (n= 9) and multi-trauma (n=8). The mean age of all patients was 60 (±16) years and the mean APACHE II score was 13 (±5) (see Table 2 ). The mean age was similar in the different groups, but the APACHE II score differed significantly between groups.
In the cardiac surgery group a number of significant co-morbidities were identified: obstructive sleep 
Infusion Rates
The median infusion rate of dexmedetomidine at the start was 0.3 (interquartile range (IQR) 0.2-0.4) µg/kg/h which remained at this level for the first six hours. It was noted that the median infusion rate at six hours in patients who were under 70 years old was higher than in those over 70 years old (0.4 µg/kg/h compared to 0.2 µg/kg/h respectively, P=0.03). Similarly the median infusion rate for the trauma group at six hours was significantly higher than the cardiac or surgical groups (0.6 µg/kg/h versus 0.3 µg/kg/h and 0.4 µg/kg/h, P=0.01).
Heart Rate
The mean heart rate on starting dexmedetomidine was 85 (±17) bpm and this fell to the lowest mean of 78 (±13) bpm (P<0.0001) at four hours. This rate was sustained for the duration of the infusion. This reduction was statistically significant, however it was not clinically relevant as no intervention was required ( Figure 1 ). Six patients had a recorded sinus bradycardia of below 60 at some time during the study, and three of these had heart rates below 60 at the time of commencement of infusion. No specific therapy was required to treat the bradycardia. In the cardiac group, 14 patients returned from theatre with temporary epicardial pacing wires, and a further two had a permanent pacemaker in situ. When these patients were excluded from our analysis, the mean baseline heart rate was 88 (±19) bpm which rose to 90 (±19) bpm at one hour, and then remained at 78 (±14) from four hours onwards. The heart rate changes over the first six hours were statically significant (P<0.0001), but again not clinically relevant.
Systemic Blood Pressure
The mean systolic blood pressure at the start of the infusion was 125 (±22) mmHg and this fell to 112 (±20) mmHg (P=0.009) at 1.5 hours after which there was minimal change for the duration of the infusion (Figure 1) . Similarly, the mean diastolic blood pressure decreased from 61 (±12) mmHg prior to dexmedetomidine to 57 (±11)mmHg at 1.5 hours but this was not statistically significant.
Pulmonary Artery Catheter Data
Twenty-four cardiac patients had pulmonary artery catheters in situ. There was minimal change in the mean systolic and diastolic pulmonary artery pressures throughout the duration of the infusion.
Inotropes and Pressors
Nine patients (18%) were receiving inotropes and/or pressors [adrenaline (n=2), noradrenaline (n=8) and/or dopamine (n=2)] prior to commencement of dexmedetomidine. There was no apparent increase in concurrent inotropes or pressors after commencement of the infusion. Six patients (12%; 5 cardiac and 1 surgical) required inotropes and/or pressors to be commenced during the first six hours of 743 
CONTINUOUS INFUSION OF DEXMEDETOMIDINE
Rescue Sedation and Analgesia
Overall, 42% of patients received dexmedetomidine as a single agent, and an additional 38% required only minimal rescue with analgesic and/or sedative agents ( Table 3 ). The cardiac patients (18/33) were more likely to receive dexmedetomidine as the single agent compared to the surgical (2/9) and trauma groups (1/8), (P=0.04). At the time of commencement of dexmedetomidine 39% (17/44) of patients with documented sedation scores were sedated in the target range (mMAAS of 0 or -1) and 45% (20 out of 44) were over sedated (mMAAS of -2 or -3). The percentage of adequately sedated patients rose to 78% at four hours and then 86% at 12 hours.
Tracheal Extubations on Dexmedetomidine
Thirty-five (70%) of all patients were extubated with the dexmedetomidine infusion still running. Cardiac patients (29/33) were more likely to be extubated under such circumstances than surgical patients (4/9) and trauma patients (2/8), (P=0.001).
Reasons for Stopping Dexmedetomidine
In 10 (20%) patients dexmedetomidine was replaced with other agents because of inadequate sedation or analgesia (cardiac 1/33, surgical 4/9 and trauma 5/8). All of these patients reached the maximum doses of dexmedetomidine infusion. In nine of these, significant doses of rescue agents were needed (midazolam 0.5-5 mg/h, and morphine 4-8 mg/h).
DISCUSSION
We have examined the short-term effect of dex-medetomidine in surgical and trauma patients. The primary difference in our protocol to that of previously published data with similar patients was the exclusion of the loading dose. Venn and co-workers (1999) reported an incidence of 27% significant haemodynamic changes of which 61% occurred during the loading dose phase, with some patients being withdrawn from the study as a result 5 . Conversely, Herr and co-workers reported a rise in systolic blood pressure within the first 30 minutes using a modified loading dose of dexmedetomidine in postoperative cardiac surgery patients 7 . This may be explained by the different baseline used by this study (pre-sternal closure). In comparison, our data showed a reduction of 8% in heart rate and 10% in systolic blood pressure from baseline after the commencement of dexmedetomidine. None of our patients had a clinically significant bradycardia, and only six patients (12%) required the introduction of a pressor for management of low blood pressure. However, the absence of a control group makes it difficult to identify a direct cause and effect in this group of patients where significant fluid shifts, blood loss and dynamic changes are likely to be occurring in the postoperative period. Postoperative warming in the cardiac surgery group and the concurrent use of inotropes and pressors may mask the true effect on blood pressure. None of the six patients with heart rates below 60 demonstrated any clinically significant sequelae and treatment of bradycardia was not required. When the patients with pacing wires were excluded from analysis, the effect on mean heart rate was identical to the whole group, which suggested that the presence of an artificial pacing system did not conceal any significant negative chronotropic effect of dexmedetomidine. From our pulmonary artery catheter data, there appears to have been no significant effect on pulmonary artery pressures although not enough cardiac output data was collected to make a meaningful interpretation.
Our patients came from a diverse group in terms of underlying pathology, APACHE II score and age. The cardiac group's median age of 60 years was lower than expected. Some patients were commenced on dexmedetomidine immediately after returning from surgery to the intensive care unit, while others were changed to dexmedetomidine after receiving sedation with different agents. The ability of dexmedetomidine to provide adequate sedation and analgesia in the absence of respiratory depression allowed the inclusion of patients with severe co-morbidities (as described earlier). In some patients dexmedetomidine was specifically introduced in an attempt to gain 744 M. ICKERINGILL, Y. SHEHABI ET AL *Rescue sedation requirement between different groups, P<0.0001. "Minimal" additional sedation is <10 mg midazolam/day or <100 mg propofol/day and "significant" is 10 mg midazolam/day or 100 mg propofol/day. "Minimal" additional analgesia is <10 mg morphine/day and "significant" is 10 mg morphine/day. control of sedation in difficult cases. Our finding of a significantly lower dexmedetomidine requirement in the over 70 age group suggests that older patients may be more sensitive to dexmedetomidine. The Motor Activity Assessment Scale has been validated and shown to be reliable in critically ill patients 8 . Our modification, we believe, is an aid to easier titration of sedative agents by targeting a score of zero. However these sedation scales were developed around the use of more traditional hypnotic sedative agents and it may not be possible to extrapolate their use to alpha 2 agonist sedative agents. Quality of sedation may best be measured by the long-term impact of sedation and analgesia.
The incidence of delirium, critical illness polyneuropathy and post-traumatic stress disorder are some of the indices that warrant further investigation.
Overall, 76% of patients required no rescue sedation and 48% required no rescue analgesia. Of those requiring rescue analgesia, only seven (14%) required significant additional analgesia. This is fairly comparable to other published data by Venn and colleagues in 2003 and Herr and colleagues in 2003. The cardiac group required the least additional sedation and or analgesia. The trauma group required significantly more rescue sedative agents (6/8) than the other two groups while the surgical group required significantly more analgesia than the cardiac group. In the seven patients who required opioid analgesia in excess of 10 mg of morphine or equivalent over 24 hours, five also required sedation in excess of 10 mg midazolam or 100 mg propofol in the same time period. It is likely that no single agent would have been adequate in providing the sedation/analgesia for this small group.
The sedation protocol was nurse-driven and nurses' perception of comfort in trauma victims may have influenced the level of sedation used for this group. This group had a lower mean age and many of the patients had been involved in psychologically damaging events. The subjectivity of the bedside nurse and the potential diurnal variation in sedation practice may produce a significant confounding effect that can only be assessed in a blinded study. Whilst there is no agreed maximum dose for morphine or midazolam, the registered maximum dose allowable for dexmedetomidine limited our ability in this study to explore the full potential of this drug.
Overall, dexmedetomidine was more effective as a sole agent in cardiac surgery patients and least effective in multiple trauma patients. At the present recommended dose of up to 0.7 µg/kg/h, dexmedetomidine is not sufficient to act predictably as a single agent in all groups of patients and larger doses may be required, as suggested by other authors 6 .
Finally, we have demonstrated that by avoiding a loading dose of dexmedetomidine, unwanted cardiovascular effects can be substantially minimized. This technique of administering dexmedetomidine is now our standard practice.
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